根据名称进行药物检索

Adipex 与 Zyvox (Linezolid Injection)

Adipex 与 Zyvox (Linezolid Injection)互相作用以及同时服用的可能性。

检测结果:

Adipex <> Zyvox (Linezolid Injection)

现实性: 19.05.2023 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

使用利奈唑一起芬特明，不建议。结合这些药物可能引起危险的高血压力和甚至死亡。你可以使用苯丁胺只有在你已经关闭利奈唑至少14天。你应该立即寻求医疗照顾，如果你的经验突然和剧烈头痛、视力模糊、混乱、缉获、胸部疼痛、恶心、呕吐，突然麻木或薄弱(特别是对身体的一边)，语言困难、发热、出汗、头晕、和/或昏倒在治疗过程中与利奈唑，因为这些可能的迹象和症状的过高血压力。重要的是要告诉你的医生关于所有其他药物的使用，包括维生素和草药。不停止使用任何药物，没有第一个说你的医生。

医界专家:

禁忌：集中作用的交感神经剂(即中枢神经系统兴奋剂)，特别是苯丙胺和苯丙胺衍生物，可沉淀物的严重高血压的反应和次高烧患者治疗单胺氧化酶抑制剂(单胺氧化抑制剂). 死亡已经发生的一些报告的情况。该机制涉及协同的交感神经的效果，由于增强降肾上腺素存储在肾上腺素能神经元(单胺氧化酶抑制剂的活动)和增强的解放，或降低重吸收儿茶酚胺(中央交感神经活性)。单胺氧化抑制剂还慢苯丙胺的新陈代谢，这可能会加强安非他明的效果在释放的去甲肾上腺素和其他单胺从肾上腺素能神经末梢。

管理：在一般情况下，中枢神经系统兴奋剂中不应使用同时或单胺氧化抑制剂和其他药剂，拥有单胺氧化酶抑制剂的活动(例如痢特灵，利奈唑胺、亚甲基蓝色，丙卡巴肼). 至少14天应之间停止的单胺氧化酶抑制剂疗法和治疗开始与中枢神经系统兴奋剂。

来源

Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5
"Product Information. Adderall (amphetamine-dextroamphetamine)" Shire Richwood Pharmaceutical Company, Florence, KY.
Markowitz JS, Patrick KS "Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder." Clin Pharmacokinet 40 (2001): 753-72
"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc, Florence, KY.
Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7
De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5
Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36
Krisko I, Lewis E, Johnson JE "Severe hyperpyrexia due to tranylcypromine-amphetamine toxicity." Ann Intern Med 70 (1969): 559-64
Elis J, Laurence DR, Mattie H, Prichard BN "Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure." Br Med J 2 (1967): 75-8
Sjoqvist F "Psychotropic drugs (2) interaction between monoamine oxidase (MAO) inhibitors and other substances." Proc R Soc Med 58 (1965): 967-78
Smookler S, Bermudez AJ "Hypertensive crisis resulting from an MAO inhibitor and an over-the-counter appetite suppressant." Ann Intern Med 11 (1982): 482-4
Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6
Dally PJ "Fatal reaction associated with tranylcypromine and methylamphetamine." Lancet 1 (1962): 1235-6
Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62
Wright SP "Hazards with monoamine-oxidase inhibitors: a persistent problem." Lancet 1 (1978): 284-5
"Product Information. Dexedrine (dextroamphetamine)" SmithKline Beecham, Philadelphia, PA.
Harrison WM, McGrath PJ, Stewart JW, Quitkin F "MAOIs and hypertensive crises: the role of OTC drugs." J Clin Psychiatry 50 (1989): 64-5
"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company, Indianapolis, IN.
Schildkraut JJ, Klerman GL, Friend DG, Greenblatt M "Biochemical and pressor effects of oral d,l-dihydroxyphenylalanine in patients pretreated with antidepressant drugs." Ann N Y Acad Sci 107 (1963): 1005-15
Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31
"Product Information. Focalin (dexmethylphenidate)." Mikart Inc, Atlanta, GA.
"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals, East Hanover, NJ.